Natera Shares Climb After Narrower 3Q Loss, 4Q Guidance Beat Expectations
Natera's stock rose 12% after reporting better-than-expected Q3 results and strong Q4 outlook. The genetic testing company's revenue surged by 64%, with a net loss of $31.6 million. Analysts predict revenue to reach $1.61-1.